The World Cancer Congress, organized every two years by the Union for International Cancer Control, is the flagship international meeting on cancer control. It draws researchers, clinicians, advocates, policymakers, and people with lived experience from more than 120 countries, making it a natural stage for work that sits at the intersection of clinical medicine and public health policy. Representing the network’s Global Policy team in Hong Kong are Matt Izzo, MPP, Senior Specialist for Global Policy and Strategic Alliances, and Stephanie Montesino, MPH, a Global Policy and Advocacy Fellow, each presenting one of the two abstracts. The organization also maintains an informational booth at the congress where attendees can learn about its international programs and collect free patient resources.

Crystal S. Denlinger, MD, Chief Executive Officer of the network, framed the stakes in a statement released ahead of the meeting. The congress, she said, offers a unique opportunity to engage with key decision-makers worldwide regarding cancer care and policy. Everyone, she argued, should have access to the best possible cancer prevention and treatment regardless of where they are located, and she expressed pride in sharing what the network and its in-country collaborators are doing to improve cancer outcomes around the globe while working with others to build on that success. That framing matters, because the two abstracts presented in Hong Kong are not merely academic exercises; they are evidence for a policy argument that regionally appropriate guidelines belong at the center of national cancer planning.

The first abstract, titled “The Inclusion of Clinical Practice Guidelines in National Cancer Control Plans,” examines a class of documents that most people outside health ministries have never heard of but that shape care for millions. National Cancer Control Plans are government-led public health initiatives that lay out clearly defined processes for cancer prevention, screening, and treatment. They are, in effect, a country’s master blueprint for reducing its cancer burden. The research team’s findings offer both encouragement and a warning. On the encouraging side, 61 percent of active national cancer control plans include references to existing national or international cancer treatment guidelines, and another 19 percent include strategies for developing such guidelines. Taken together, that means roughly four in five plans at least acknowledge the role of structured clinical guidance.

The warning lies in the details. While the vast majority of the plans studied, 86 percent, feature strategies for implementing the use of guidelines more broadly, most of them overlook the systems needed to measure whether that implementation actually happens, and whether it happens equitably and with quality. A plan that tells clinicians to follow guidelines but never checks whether they do, or whether patients in rural and underserved regions receive the same standard of care as those in major cities, leaves the hardest part of the work undone. The research also identified significant room for growth in incorporating guidance on disease staging, the systematic classification of how far a cancer has progressed. Staging is critical for identifying population-level trends and for designing targeted interventions, yet it remains underdeveloped in many national plans.

The second abstract shifts from policy documents to clinical practice. Titled “Enhancing Nasopharyngeal Carcinoma Care in China Through Adapted Clinical Guidelines,” it was authored jointly with Dr. Jun Ma and Dr. Ying Sun, both Chief Physicians and Radiation Oncologists at Sun Yat-sen University Cancer Center in Guangzhou, China. The abstract explains how the network worked with local experts in China to create the Chinese Editorial Committee, a body that then adapted the network’s Clinical Practice Guidelines in Oncology for Head and Neck Cancers into a dedicated Chinese edition covering cancer of the nasopharynx. The goal was to tailor recommendations to regional clinical practice and resource availability, producing a practical, context-specific framework for elevating the management of nasopharyngeal cancers across diverse clinical settings in China.

The choice of nasopharyngeal carcinoma is not incidental. Dr. Ma, in comments provided with the release, noted that the disease is substantially more common in China than in the United States, reflecting a combination of Epstein-Barr virus-related, genetic, and environmental factors. That higher disease burden has generated extensive local clinical experience and, in places, meaningful differences in practice compared with American norms. Local experts were therefore able to suggest several adaptations to the original guidelines based on clinical data from China. These included the addition of medications that are available in China but not necessarily elsewhere, as well as the expansion of some systemic therapy and radiation therapy recommendations. The result, Dr. Ma said, is a set of guidelines built on the network’s time-tested methods but optimized for people in China, and he described the underlying guidelines as the gold standard, shown to improve the quality, effectiveness, equitability, and accessibility of cancer care around the world.

The scale of the adaptation effort is considerable. Nearly half of all registered users of the network’s guidelines are international professionals, with the largest concentrations in China, India, South Korea, Brazil, Mexico, Japan, Thailand, Canada, Spain, and Italy. Across the globe there are now more than 90 international adaptations of the guidelines and more than 180 different translations in numerous languages. Those numbers describe something rare in medicine: a single, continuously updated evidence framework that is simultaneously authoritative enough to anchor practice in Boston or Houston and flexible enough to be reworked for the drug formularies, diagnostic capacity, and epidemiology of Guangzhou or Mexico City. All of the organization’s global cancer resources are available for free through its website or its Virtual Library mobile app.

What emerges from the two abstracts is a coherent model. On one side, the analysis of national cancer control plans shows that governments are already reaching for clinical guidelines but frequently stop short of the measurement and staging infrastructure that turns a written recommendation into measurable, equitable care. On the other side, the China collaboration demonstrates what disciplined adaptation looks like: a standing editorial committee of local experts, a defined process for incorporating region-specific clinical data and drug availability, and a commitment to preserving the evidence-based methodology of the original while adjusting its content. Presented together at a congress attended by policymakers from more than 120 countries, the two pieces of research make a case that could reshape how the next generation of national cancer plans is written, with guidelines that are not just referenced but implemented, measured, and honestly tailored to the populations they are meant to serve.

Subject of Research: Adapting clinical practice guidelines for regional cancer care and national cancer control planning

Article Title: NCCN models how to tailor cancer care for different regions during 2026 World Cancer Congress

Article References: NCCN models how to tailor cancer care for different regions during 2026 World Cancer Congress. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: NCCN, World Cancer Congress, national cancer control plans, clinical practice guidelines, nasopharyngeal carcinoma, China, UICC, global health policy, guideline adaptation, cancer care equity, Sun Yat-sen University Cancer Center, head and neck cancers